دورية أكاديمية
SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro.
| العنوان: | SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro. |
|---|---|
| المؤلفون: | Penetra SLS; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Santos HFP; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Resende PC; Laboratory of Respiratory Viruses and Measles National Influenza Centre, Americas Regional Reference Lab for Measles and Rubella, Reference Laboratory for COVID-19 World Health Organization, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Bastos LS; Scientific Computing Program, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., da Silva MFB; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Pina-Costa A; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Lopes RS; Laboratory of Respiratory Viruses and Measles National Influenza Centre, Americas Regional Reference Lab for Measles and Rubella, Reference Laboratory for COVID-19 World Health Organization, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Saboia-Vahia L; Laboratory of Respiratory Viruses and Measles National Influenza Centre, Americas Regional Reference Lab for Measles and Rubella, Reference Laboratory for COVID-19 World Health Organization, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., de Oliveira ACA; Laboratory of Respiratory Viruses and Measles National Influenza Centre, Americas Regional Reference Lab for Measles and Rubella, Reference Laboratory for COVID-19 World Health Organization, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Pereira EC; Laboratory of Respiratory Viruses and Measles National Influenza Centre, Americas Regional Reference Lab for Measles and Rubella, Reference Laboratory for COVID-19 World Health Organization, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Filho FM; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Wakimoto MD; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Calvet GA; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Fuller TL; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil.; University of California, Los Angeles, Los Angeles, California, USA., Whitworth J; International Public Health, London School of Hygiene and Tropical Medicine, London, United Kingdom., Smith C; International Public Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan., Nielsen-Saines K; University of California, Los Angeles, Los Angeles, California, USA., Carvalho MS; Scientific Computing Program, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Espíndola OM; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Guaraldo L; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Siqueira MM; Laboratory of Respiratory Viruses and Measles National Influenza Centre, Americas Regional Reference Lab for Measles and Rubella, Reference Laboratory for COVID-19 World Health Organization, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil., Brasil P; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil. |
| المصدر: | The Journal of infectious diseases [J Infect Dis] 2023 Dec 20; Vol. 228 (12), pp. 1680-1689. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press |
| مواضيع طبية MeSH: | SARS-CoV-2* , COVID-19*/epidemiology , COVID-19*/prevention & control, Humans ; Prospective Studies ; Reinfection/epidemiology ; COVID-19 Vaccines ; Brazil/epidemiology |
| مستخلص: | This was a household-based prospective cohort study conducted in Rio de Janeiro, in which people with laboratory-confirmed coronavirus disease 2019 (COVID-19) and their household contacts were followed from April 2020 through June 2022. Ninety-eight reinfections were identified, with 71 (72.5%) confirmed by genomic analyses and lineage definition in both infections. During the pre-Omicron period, 1 dose of any COVID-19 vaccine was associated with a reduced risk of reinfection, but during the Omicron period not even booster vaccines had this effect. Most reinfections were asymptomatic or milder in comparison with primary infections, a justification for continuing active surveillance to detect infections in vaccinated individuals. Our findings demonstrated that vaccination may not prevent infection or reinfection with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). Therefore we highlight the need to continuously update the antigenic target of SARS CoV-2 vaccines and administer booster doses to the population regularly, a strategy well established in the development of vaccines for influenza immunization programs. Competing Interests: Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| References: | Lancet Infect Dis. 2021 Jan;21(1):52-58. (PMID: 33058797) Lancet Microbe. 2021 Dec;2(12):e715-e725. (PMID: 35544110) Lancet Reg Health Am. 2022 Aug;12:100283. (PMID: 35663637) Cell. 2020 Dec 23;183(7):1901-1912.e9. (PMID: 33248470) Eur J Clin Invest. 2022 Oct;52(10):e13845. (PMID: 35904405) J Infect Dis. 2023 Mar 28;227(6):800-805. (PMID: 36625675) J Investig Med. 2021 Aug;69(6):1253-1255. (PMID: 34006572) Occup Environ Med. 2022 Feb;79(2):116-119. (PMID: 34880045) Nat Microbiol. 2020 Nov;5(11):1403-1407. (PMID: 32669681) Viruses. 2022 Jan 23;14(2):. (PMID: 35215811) Emerg Infect Dis. 2021 Jul;27(7):1789-1794. (PMID: 33883059) Viruses. 2022 Dec 05;14(12):. (PMID: 36560720) PLoS One. 2021 Dec 9;16(12):e0261221. (PMID: 34882750) Lancet Respir Med. 2023 May;11(5):439-452. (PMID: 36780914) Lancet Infect Dis. 2023 May;23(5):556-567. (PMID: 36681084) Lancet Infect Dis. 2023 Feb;23(2):153-154. (PMID: 36640795) Sci Rep. 2023 May 8;13(1):7437. (PMID: 37156846) J Infect Dis. 2021 Jun 4;223(11):2013-2014. (PMID: 33037878) Emerg Infect Dis. 2022 Nov;28(11):2341-2343. (PMID: 36150518) Nat Commun. 2022 Aug 12;13(1):4738. (PMID: 35961956) Front Immunol. 2022 Apr 29;13:877101. (PMID: 35572518) Euro Surveill. 2022 May;27(20):. (PMID: 35593164) MedComm (2020). 2021 Dec 16;2(4):838-845. (PMID: 34957469) J Virol. 2021 Mar 1;95(10):. (PMID: 33649194) Science. 2022 May 6;376(6593):eabn4947. (PMID: 35289632) Nat Med. 2021 Jul;27(7):1230-1238. (PMID: 34035535) Int J Infect Dis. 2022 Oct;123:9-16. (PMID: 35931371) Cell Rep Med. 2023 Jan 17;4(1):100898. (PMID: 36584684) JAMA Netw Open. 2022 Aug 1;5(8):e2225320. (PMID: 35921113) Pediatr Res. 2002 Sep;52(3):363-7. (PMID: 12193668) Front Microbiol. 2021 Feb 17;11:615280. (PMID: 33679622) Emerg Microbes Infect. 2022 Dec;11(1):2383-2392. (PMID: 36069511) Thorax. 2022 Sep;77(9):900-912. (PMID: 34848555) N Engl J Med. 2022 Jun 9;386(23):2201-2212. (PMID: 35613036) |
| معلومات مُعتمدة: | MR/V033530/1 United Kingdom MRC_ Medical Research Council; R01 AI140718 United States AI NIAID NIH HHS; R21 AI129534 United States AI NIAID NIH HHS; R56 AI172252 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: COVID-19; Omicron; SARS-CoV-2 infection; reinfections; vaccine breakthrough; variants of concern |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) |
| تواريخ الأحداث: | Date Created: 20230812 Date Completed: 20231222 Latest Revision: 20240528 |
| رمز التحديث: | 20240528 |
| مُعرف محوري في PubMed: | PMC11032242 |
| DOI: | 10.1093/infdis/jiad336 |
| PMID: | 37571849 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiad336 |